Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436642 | 0.83 | KCNK3 (0.77) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL3209880 | 0.83 | KDM4E (0.73) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL28498495 | 0.82 | RAB9A (0.71) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL27941961 | 0.82 | RAB9A (0.71) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL11590385 | 0.82 | KMT2A (0.83) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL9208778 | 0.82 | NPC1 (0.71) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL30726106 | 0.82 | NPC1 (0.71) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL1499642 | 0.82 | RAB9A (1.00) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL30758588 | 0.82 | RAB9A (1.00) | KMT2AHPGDNPC1RAB9AGAA | |
| SCHEMBL8855649 | 0.81 | KMT2A (0.68) | KMT2ANPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | SLC10A2, TCERG1, SBDS | KMT2A 1871/4885HPGD 1955/4885NPC1 1532/4885 |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | KMT2A 1871/4885HPGD 1955/4885NPC1 1532/4885 |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | KMT2A 1871/4885HPGD 1955/4885NPC1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.